Skip to main content

Table 7 Antimicrobial sensitivity pattern of the hemolytic toxin harboring E. coli isolates (hly+cnf1+clbA+clbQ+) versus the non-hemolytic non-toxin harboring E. coli isolates (hlycnf1clbAclbQ) against 11 antimicrobial agents

From: Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses

Isolate code Resistance profile Genetic pattern
SXT 25 CRO 30 AMC 30 CAZ 30 LEVO 30 CIP 5 OFL 5 GAT 5 F 300 NA 30 DO 30 cnf-1 clb A clb Q
ATCC 25299 S S S S S S S S S S S +
Hemolytic toxin harboring E. coli isolates (hly+cnf1+clbA+clbQ+)
 4β R R I R S S S S S S S + + +
 5β R R R R R R R R S R R +
 6β S S S S S S S S S S S + + +
 10β R S R S R R R R S R R + + +
 27β S R S I S S S S S S S + + +
 28β R S S R S S S S S R R + + +
 29β S S S S S S S S S S S + + +
 70β S S S R S S S S S S S + + +
 99β R S S I S S S S S S S + +
 114β R R S S S S S S S S S + + +
 Percent sensitive 40% 60% 70% 40% 80% 80% 80% 80% 100% 70% 70%    
 Percent intermediate 0 0 10% 20% 0 0 0 0 0 0 0
Non hemolytic non-toxin harboring E. coli isolates (hlycnf1clbAclbQ)
 20 R S I R S S S S S S R
 45 R R R R I I S S S S R
 52 R R R R R R I I S S R
 58 R R R R R R R R S S R
 63 R R R R R R R R S S R
 67 R R R R R R R R S I R
 69 R R R R R R R R S I R
 74 R R R R R R R R S R R
 93 R S S R S S S S S S S
 120 R R R R R R R R R I R
 Percent resistance 100% 80% 80% 100% 70% 70% 60% 60% 10% 10% 100%  
 Percent intermediate 0% 0% 10% 0% 10% 10% 10% 10% 0% 30% 0%
  1. SXT trimethoprim/sulfamethoxazole 1.25/30 µg, CRO ceftriaxone 30 µg, AMC amoxicillin/clavulanic acid 20/10 µg, CAZ ceftazidime 30 µg, LEVO levofloxacin 30 µg, CIP ciprofloxacin 5 µg, OFL ofloxacin 5 µg, GAT gatifloxacin 5 µg, F nitrofurantoin 300 µg, NA nalidixic acid 30 µg, DO doxycycline 30 µg